Skip to contentB
BioCardia, Inc.
B
BCDABioCardia, Inc. Q3 2024 · 10-Q
Revenue$0.00$0.00−100.0% vs Q3 2023 Net Income-$1.74M-$1.74MN/M vs Q3 2023 EPS, diluted—
Operating Income-$1,756,000N/M Operating Cash Flowderived-$2,611,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioCardia, Inc. · CIK 925741 · Engraved from SEC EDGAR
Free Cash Flowderived-$2,613,000N/M ended Sep 30, 2024 · filed Nov 13, 2024 · 44 d after period end